Announcing FierceMedicalDevices

"When are you launching FierceMedicalDevices?" 

That's the number one request the Fierce Life Sciences team receives from our readers. You asked loudly, and now I have an answer: We're launching tomorrow, Wednesday, March 24.

Our goal is simple: Be the first place you turn for medical devices and diagnostics news and insight. We've designed a weekly report readers will find relevant, timely, and most importantly, Fierce. As a current FiercePharmaManufacturing subscriber, you're entitled to an easy one-click sign-up by clicking below:

Click here to activate your complimentary FierceMedicalDevices subscription - one click.

FierceMedicalDevices will be delivered every Wednesday by e-mail, and FierceMedicalDevices.com will be updated throughout the week as news breaks. Real-time news consumers will find @FierceMedDev on Twitter another valuable resource.

We've got our eyes on key regulatory decisions, clinical studies, research and development, post-marketing, and dealmaking in medical devices and diagnostics. But we also need your news and tips: Maureen Martino and Liz Jones will lead our editorial coverage. Readers and key industry influencers should reach out directly to them.

Your feedback led to the launch of this publication, and your participation in the Fierce community is greatly appreciated. If you're involved in the medical devices or diagnostics fields, we think you're going to love FierceMedicalDevices.

- Arsalan Arif (e-mail me | follow me on Twitter)
Group Publisher, FierceMarkets Life Sciences

PS: Click here for one-click sign-up to FierceMedicalDevices. Your first newsletter will be delivered Wednesday, March 24.

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.